Cargando…

Chromatin accessibility landscape of relapsed pediatric B-lineage acute lymphoblastic leukemia

For around half of the pediatric B-lineage acute lymphoblastic leukemia (B-ALL) patients, the molecular mechanism of relapse remains unclear. To fill this gap in knowledge, here we characterize the chromatin accessibility landscape in pediatric relapsed B-ALL. We observe rewired accessible chromatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Han, Sun, Huiying, Liang, Bilin, Zhang, Fang, Yang, Fan, Cui, Bowen, Ding, Lixia, Wang, Xiang, Wang, Ronghua, Cai, Jiaoyang, Tang, Yanjing, Rao, Jianan, Hu, Wenting, Zhao, Shuang, Wu, Wenyan, Chen, Xiaoxiao, Wu, Kefei, Lai, Junchen, Xie, Yangyang, Li, Benshang, Tang, Jingyan, Shen, Shuhong, Liu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600232/
https://www.ncbi.nlm.nih.gov/pubmed/37880218
http://dx.doi.org/10.1038/s41467-023-42565-z
Descripción
Sumario:For around half of the pediatric B-lineage acute lymphoblastic leukemia (B-ALL) patients, the molecular mechanism of relapse remains unclear. To fill this gap in knowledge, here we characterize the chromatin accessibility landscape in pediatric relapsed B-ALL. We observe rewired accessible chromatin regions (ACRs) associated with transcription dysregulation in leukemia cells as compared with normal B-cell progenitors. We show that over a quarter of the ACRs in B-ALL are in quiescent regions with high heterogeneity among B-ALLs. We identify subtype-specific and allele-imbalanced chromatin accessibility by integrating multi-omics data. By characterizing the differential ACRs between diagnosis and relapse in B-ALL, we identify alterations in chromatin accessibility during drug treatment. Further analysis of ACRs associated with relapse free survival leads to the identification of a subgroup of B-ALL which show early relapse. These data provide an advanced and integrative portrait of the importance of chromatin accessibility alterations in tumorigenesis and drug responses.